

Evaluation of Classical Ayurvedic Medicine for its Neuropharmacological Action

Sujit Dash^{1,*}, Amaresh Chandra Sahoo², Prabhat Kumar Sahoo², Sushanta Kumar Rout³, Pratik Jena¹, Rajlaxmi Barik¹, Jyotiraditya Mohapatra¹

¹Department of Pharmacognosy, Institute of Pharmacy and Technology, Salipur, Odisha, INDIA.

²Department of Pharmaceutics, Institute of Pharmacy and Technology, Salipur, Odisha, INDIA.

³Department of Science and Technology, Government of Odisha, Odisha, INDIA.

ABSTRACT

Background: The classical ayurvedic formulation Bru-satavari after consumption by people can get a restful night's sleep and feel rejuvenated. The goal of this study is to look at important phytoconstituents which may influence the neuropharmacological activities. Therefore, we made an effort to learn the methanol extract of classical ayurvedic formulation Bru-Satabari having anyneuropharmacological activity. **Materials and Methods:** The open field, hole cross, rota-rod, and thiopental sodium-induced sleeping duration tests on mice were used to examine the sedative effect of brusatavari at dosages of 400 mg/kg. The anxiety-relieving effect evaluated using the hole-board test. Compared to the positive control drug diazepam, sedative and anxiolytic effects were seen. Analgesic effect was evaluated by tail flick method. **Results:** According to the study, the extract has remarkable neuropharmacological action because it lowers mice's anxiety and locomotor activity in all instances of hole cross, open field, and rota rot tests when compared to the control. Additionally, compared to the standard and control group, the extract extends sleep time with a rapid onset of effect. Further the Bru-satavari exhibited excellent analgesic activity in comparison to control. **Conclusion:** The findings confirm the use of Bru-Satabari in traditional medicine by showing that it exhibits sedative and anxiolytic properties. Best suggested: More research into the drug's mechanism of action and the isolation of its active compounds.

Keywords: Bru-Satabari Sedative, Anxiolytic, Thiopental sodium-induced sleeping test, Neuropharmacology.

Correspondence:

Dr. Sujit Dash,

Asstiant Professor,
Institute of Pharmacy & Technology,
Salipur, Odisha, INDIA.

Email : discoversujit@gmail.com

ORCID ID: 0000-0003-4764-2062

Received: 21-12-2022;

Revised: 17-02-2023;

Accepted: 30-03-2023.

INTRODUCTION

The research upon neuropharmacology investigates how drugs alter the working of cells in the sensory system and also neurological systems through influencing behaviors and actions.¹ Neuropharmacology comprises two main parts: behavioral and molecular. Competence Neuroscience focuses on the effect of medications on the actions of people (neuropsychopharmacology), particularly the study of drug addiction and dependence on the cognitive system.² The examination of neurons, particularly their combinatorial communications, involves molecular neuropharmacology with the aim of producing medicines that impact neurologic potentials. In stressful conditions, the body goes into "fight or flight" mode to fine-tune cognitive capabilities and actions while also protecting itself from imagined damage. Specific

brain chemical substances like endocannabinoids are generated throughout this procedure to aid the physique in its maximum performance. In motor function, cognitive function, emotions, and behavior, endocannabinoids play a significant role. Notably, studies reveal that marijuana, generally referred to as marijuana, comprises endocannabinoids as well as a number of cannabinoids, which can also be favorable for the behaviour of a mouse.³⁻⁵ However, chronic marijuana use may lead to dependence and other adverse side effects.⁶

The ayurvedic drug Bru Satabari contains Satabari- *Asparagus racemosus*, Sunthi- *Gingiber officinalis*, Amla- *Phyllanthus emblica*, Elaichi- *Ellettaria cardamomum*, Dalchini- *Cinnamomum zeylanicum*, Labanga- *Syzygium aromaticum*, Raktachandan- *Pterocarpus santalinus*, Milk, Sugar, Kesar- *Crocus sativus*, Madhuri- *Foeniculum vulgare*, Bhanga- *Cannabis sativa*. It is stated that Bru-Satabaria a classical ayurvedic medicines has a Bazikaran Dhatu Berdhak constipation relaxation effect. Because of the inclusion of cannabis in the preparation, this medicine may also have implications on the CNS and peripheral nervous system. Tests on the bioactive ingredients and behavioral



DOI: 10.5530/ijpi.13.3.062

Copyright Information :

Copyright Author (s) 2023 Distributed under
Creative Commons CC-BY 4.0

Publishing Partner : EManuscript Tech. [www.emanuscript.in]

neuropharmacological activity of conventional ayurvedic medicine in rats were carried out to ensure the quality, purity, and behavioral neuropharmacological effectiveness of the chosen pharmaceutical formulations.

MATERIALS AND METHODS

High performance thin layer chromatography

The HPTLC technique is a sophisticated and automated separation technique that was developed from TLC. Pre-coated HPTLC rated plates and an auto sampler were used to achieve accuracy, sensitivity, and significant separation on both a qualitative and quantitative level. Cannabis is readily soluble in the majority of organic solvents, including methanol, petroleum ether, n-hexane, toluene, chloroform, and solvent blends like methanol:chloroform (9:1). 500 mg of the Bru-Satavari ayurvedic formulation are extracted using the following procedure using 5 ml of methanol: chloroform (9:1 v/v): After centrifugation, there is a 15-minute ultrasonic bath with three additional vortexing periods of 5, 10, and 15. Chromatographic analysis was conducted using ⁷HPTLC plates that were 10 cm x 20 cm in size. Linomat IV sample applicator was used to apply samples in bands 6 mm wide and 8 mm apart. The sample was put onto the plate at a rate of 160 nL/s. The plates were formed in a previously saturated 20 cm x 10 cm twin-trough glass container using n-hexane, dioxane, and methanol (7:2:1) as the mobile phase under ambient temperature and humidity conditions (25 and 2%, respectively). These plates were allowed to stand at room temperature before being heated to reveal compact bands. Qualitative evaluation was done using CATS 4 and WinCATS software Version 1.2.0 in reflectance mode at wavelengths of 254 and 366 nm.⁸

FTIR

ATR FTIR spectra were recorded on a Diamond Crystal ATR (Attenuated Total Internal Reflectance) attachment for the Bruker-Alpha II FTIR spectrometer. Vacuum evaporated methanol extract of Bru Satavari was applied enough to coat the crystal with approximately 1 mm thickness of material. The sample was placed under the pressure arm, which then exerted pressure on it. Opus 7.8 software was used to operate the spectrometer. Direct placement of the sample on the diamond crystal plate. At room temperature, spectra covering the wavelength range of 4000 to 650 cm⁻¹. were all captured.⁹

GC-MS analysis

For the GC-MS analysis, 200 gm of BruSatavari were extracted with methanol. The resultant methanol extract was filtered and concentrated at 40°C under decreased pressure in a rotary evaporator. The methanol extract was subjected to the GC-MS analysis. A Chromatography-Mass Spectrometry equipment with a Thermo Trace 1300GC and a Thermo TSQ 800 Triple Quadrupole MS was used to conduct the GC-MS analysis.

These are the conditions: The 30 x 0.25mm ID x TG 5MS (30m X 0.25mm, 0.25m) Elite-1 fused silica capillary column was composed of 95% dimethyl polysiloxane and 5% diphenyl. The GC runs in electron impact mode at 70 eV. For the GC-MS analysis, 200 gm of BruSatavari were extracted with methanol. The resultant methanol extract was filtered and concentrated at 40 °C under decreased pressure in a rotary evaporator. The methanol extract was subjected to the GC-MS analysis. A Chromatography-Mass Spectrometry equipment with a Thermo Trace 1300GC and a Thermo TSQ 800 Triple Quadrupole MS was used to conduct the GC-MS analysis. These are the conditions: The 30 x 0.25mm ID x TG 5MS (30m X 0.25mm, 0.25m) Elite-1 fused silica capillary column was composed of 95% dimethyl polysiloxane and 5% diphenyl. The GC runs in electron impact mode at 70 eV. The GC runs for 44 minutes in total. By comparing and evaluating each component part's average peak area to the total areas, the relative percentage aggregate for each component part was determined. The software used to manage mass spectra and chromatograms is Turbo Mass Version 5.2.0. By percentage peak area, the BruSatavari GC-MS separated components were displayed. By comparing mass spectrum fragmentations and retention indices to values listed in NIST databases, compounds were detected.

Neuropharmacological activity

Utilizing several animal models, the methanolic extract of Bru-Satavari was studied for its neuropharmacological effects. Three groups of six rats each were used in each experiment.

This experimental design is as follows;

Group-I – Normal Control (Tween + Water).

Group-II – Diazepam 1mg/kg.

Group-III –Test (400 mg/kg body wt.).

Sedative activity

Hole cross test methodology was used to test the action of sedatives in mice. A wooden box 30×20×14cm in size was divided in the centre on which the experiment was carried out. In the centre of the box, a 3 cm diameter of the hole drilled with a 7.5 cm height. Following oral administration of the test extract, the number of mice passing through the aperture from one compartment to the other was counted for three minutes at intervals of 0, 30, 60, 120, 180, and 240 minutes.¹⁰

Locomotor and behavioural activity

In mice, the free or open space behavioural test is commonly used to assess emotional and motor behavior. Control, positive control, and test groups of animals were separated. The equipment was made of plywood was (72 cm x 72 cm x 36 cm) was composed of plywood. On the board, a half-square-meter open area is divided into a series of squares with contrasting colors (black and white).

Table 1: High performance thin layer chromatography analysis of Methanolic extract of Bru- Satabari, An ayurvedic classical medicine at 254nm.

Peak	Start position	Start height	Max position	Max Height	Max %	End position	End position	Area	Area %
1	0.06 R _f	0.3 AU	0.08 R _f	40.7 AU	4.71%	0.09 R _f	7.8 AU	423.3 AU	1.29%
2	0.25 R _f	0.1 AU	0.34 R _f	110.2 AU	85.91%	0.38 R _f	1.7 AU	8583.9 AU	56.63%
3	0.38 R _f	42.6 AU	0.43 R _f	93.1 AU	22.35%	0.48 R _f	1.2 AU	6862.2 AU	20.91%
4	0.48 R _f	6.3 AU	0.50 R _f	40.7 AU	4.71%	0.51 R _f	3.5 AU	463.4 AU	1.41%
5	0.51 R _f	34.3 AU	0.51 R _f	38.4 AU	4.45%	0.53 R _f	2.0 AU	441.2 AU	1.34%
6	0.55 R _f	12.5 AU	0.58 R _f	39.1 AU	4.53%	0.59 R _f	4.8 AU	721.8 AU	2.20%
7	0.59 R _f	35.7 AU	0.59 R _f	42.7 AU	4.95%	0.62 R _f	4.6 AU	753.1 AU	2.29%
8	0.76 R _f	41.0 AU	0.80 R _f	80.6 AU	9.33%	0.81 R _f	3.1 AU	2440.9 AU	7.44%
9	0.81 R _f	74.1 AU	0.81 R _f	78.3 AU	9.06%	0.86 R _f	7.5 AU	2125.7 AU	6.48%

Table 2: High performance thin layer chromatography analysis of Methanolic extract of Bru- Satabari, An ayurvedic classical medicine at 254nm.

Peak	Start position	Start height	Max position	Max Height	Max %	End position	End height	Area	Area %
1	0.23 R _f	4.4 AU	0.32 R _f	55.9 AU	63.65%	0.35 R _f	4.0 AU	3375.6 AU	70.99%
2	0.38 R _f	1.0 AU	0.42 R _f	36.2 AU	36.35%	0.45 R _f	3.2 AU	970.9 AU	29.01%

The open field equipment's cardboard floor was separated into 16 squares (18 cm x 18 cm). This experiment was conducted at room temperature in a darkened space. Following oral administration of the test extract for 0, 30, 60, 90, and 120 min, the number of squares each animal from each group had crossed over was counted for 3 min.¹¹

Motor coordination or grip strength activity

After receiving an oral dose of Bru-Satabari methanol extract, each new cohort of rats had their motor performance and coordination tested in a rota-rod apparatus 30 minutes later. Rats were housed on a wooden horizontal rod that rotated at rate of 20 revolutions per minute. Three groups of the animals were created (n = 6). The rats had 180 sec of rota-rod training prior to the trial. Bru-Satabari methanol extract was given orally to the test groups, whereas the control group was given 0.9 percent solvent vehicle. The animals in the positive control group received diazepam (1 mg/kg). The animals were placed in a spinning bar with a diameter of 2.5 cm and a height of 25 cm off the ground. Each rat was observed for 180 sec, which is designated performance time, and rats who failed to stay on the rota-rod more than once were regarded to have passed the test.¹²

Hypnotic activity

Thiopental sodium-induced sleeping time test was used to determine hypnotic activity. The test groups received Brusatvari methanol extract orally whereas the control group received 0.9% solvent vehicle. Animals in the positive control group received diazepam (1 mg/kg). 30 min later, thiopental sodium (40 mg/

kg, i.p.) was administered to each mouse to induce sleep. The animals' latent period (the amount of time between receiving Thiopental sodium and losing the righting response) and sleep duration were tracked (the time between the loss and recovery of righting reflex).¹³

Analgesic activity

Also monitored was analgesic action Wistar albino rat tail immersion test using caudal immersion. The tail flick test uses heat stimuli to cause pain, although the heat is different from other tests. To stimulate tail immersion, hot water is employed. The experimental animal was housed in a cage with only one-third of its tail allowed to extend outside. This animal was then submerged in a 55°C hot water bath until the rat withdrew its tail. To avoid injury, the cut-out time is roughly 180 seconds.¹⁴

RESULTS

High performance thin layer chromatography

This technique is therefore practical for routine quality control analysis. It produces a phytochemical chromatographic fingerprint that can be used to verify the authenticity and purity of raw medicinal plant materials. The High Performance Thin Layer Chromatography (HPTLC) technology offers the best accuracy and precision with the greatest degree of flexibility for varied steps. It is also the simplest and fastest separation method currently accessible. The outcomes, including the number of peaks and the highest R_f value, are reported in (Tables 1, 2 and Figures 1, 2). The extract of methanolic extract of Bru-Satabari, formulation showed 9 peaks having maximum R_f value 0.09, 0.38,




Figure 1: HPTLC analysis of methanolic extract of Bru-Satabari, a classical ayurvedic formulation at 254nm.




Figure 2: HPTLC analysis of methanolic extract of Bru-Satabari, a classical ayurvedic formulation at 366 nm.

0.48, 0.51, 0.53, 0.59, 0.62, 0.81, 0.86 at 254 nm. The methanolic extract of Bru-Satabari, showed 2 peaks having maximum R_f value 0.35, 0.45 at 366 nm. The results are reported in with the number of peaks and maximum R_f value (Tables 1 and 2)

ATR FTIR Evaluation

To demonstrate the functionalization of the cannabis present in the ayurvedic preparation Bru Satavari, the ATR FTIR spectra (4000–650 cm^{-1}) of the methanol extract of the formulation were recorded. Figure 3 shows the characteristic bands of cannabinoids around 1635, 1576, 1424, 1161, 1043 cm^{-1} (Tetrahydrocannabinol) and 1684, 1592, 1515, 1366 cm^{-1} (cannabidiol).¹⁵

GC-MS analysis Revision needed

Table 3 and Figure 4 shows the GC-MS analysis of methanolic extracts of Bru-Satabari, a traditional ayurvedic preparation. Cannabidiol, with an RT value of 13.89, was reported to even have functions such as a sleeping aid, pain reduction, and anti-tumor. Cannabidiol inhibits the progression of disorders such as Parkinson's and Alzheimer's.¹⁶ CBD acts as an inhibitor of anandamide reuptake, an inverse agonist of the CB2 receptor, as well as a non-competitive negative allosteric modifier of the CB1 receptor. DELTA-8-Tetrahydrocannabinol contains antiemetic, anxiolytic, appetite stimulant, analgesic, and neuroprotective effects.¹⁷ THC functions as a cannabinoid 1/2 (CB 1/2) receptor partial agonist. It causes the normal effects associated with

cannabis, including euphoria, relaxation, and altered perceptions. Additionally, dysphoria, anxiety, and psychotic symptoms have all been connected to THC. THC is employed to alleviate chronic pain, as an appetite stimulant, and to ease nausea and vomiting brought on by chemotherapy. THC is employed to alleviate chronic pain, as an appetite stimulant, and to ease nausea and vomiting brought on by chemotherapy.¹⁸ Cannabinol with an RT value of 14.79 has sedative, anti-convulsant, and anti-bacterial properties.¹⁹⁻²¹

Sedative activity

From 0 to 120 minutes, mice in the control group opened the same number of chambers before moving on to the next. In the hole-cross test, methanolic extract of a classical ayurvedic formulation- Bru Satabari at dose given at 400 mg kg^{-1} demonstrated a diminishing in velocity in mice from second observation period (30 min.) and was sustained up to third observation (60 min.) as appears by the decrease in multitude of holes crossed by the treated mice compared with the control group. The outcome was exactly equivalent to control group and was not statistically significant for the Bru-Satavari 400 mg/kg at 0th min to 120 min. The positive control diazepam reduced locomotion behavior in the test animal as well. The results and experimental data were shown in Table 4.

Locomotor and behavioural activity

It has been demonstrated experimentally that, in the absence of a special task to undertake, a given animal's behavior tends to sustain that inner activation level, which is sometimes inconsistent with the animals' actual level of activation. The open field test was carried out in order to get the most precise picture of the drug's effect on exploration. Methanolic extract of a classical ayurvedic formulation-Bru-Satabari 400 mg/kg reduced exploration in the open field test. However, after half an hour of the drug administration of Brusatavari produced a mark reducing effect on the exploration. The drug significantly decreased the animal on exploration ($p < 0.01$) by experimental animals in 90 and 120 min. when compared to control group. The outcome of this test was presented in Table 5.

Motor coordination or grip strength activity

It is well accepted that several benzodiazepines, such as diazepam, produce muscle relaxants, ambulatory mobility decrease, and drowsiness, lowering rat efficiency on the rota-rod. The effect of Bru-Satabari after 30 min. of oral administration at 400 mg/kg on the rota-rod test was statistically very significant ($p < 0.001$) in increasing the multitude of falls while decreasing the performance time. Muscle relaxant effects were comparable to the favourable benefits. The rota-rod test is a popular method for assessing muscle relaxant influence in animals. Treatment with Bru-Satabari increased the frequency of rats falling and lowered the time they spent performing on the revolving rod, according




Figure 3: FTIR analysis of powdered drug of Methanolic extract of Bru-Satabari, a classical ayurvedic formulation.

to our findings (Table 6). It was also discovered that diazepam promoted muscle relaxant influence in the animal's, which resulted in a longer period for them to fall in the rota-rod.

Thiopental sodium-induced sleeping

Significant ($p < 0.001$) decrease in the onset of sleep was observed in the thiopental sodium-induced sleeping time test. Furthermore, a significant ($p < 0.001$) increase in total sleeping time was observed in mice treated with Bru-Satabari methanolic extract (400 mg/kg) mg/kg when compared to the control group. The positive control group (diazepam 1 mg/kg) had a marked impact, as did the ayurvedic formulation (Table 7).

This is a standard method in cognitive and behavioural pharmacology for investigating sedative properties. In our study, the herbal remedies formulation significantly reduced sleep latency while also increasing sleep duration (Table).

Tail-immersion Test

Treatment with the Methanolic extract of a classical ayurvedic formulation-BruSatabari (400 mg/kg) showed a critical and portion subordinate antinociceptive movement in the tail immersion test. The 400 mg/kg of the Methanolic extract of a classical ayurvedic formulation-Bru Satabari expanded an antinociceptive movement in 0 min and 30 min after infusion that was equivalent to the control gathering. Under comparative conditions, treatment with morphine 5% mg/kg

altogether expanded dormancy to warm incitement 45 min after organization and the antinociceptive impact was kept up amid the whole time of assessment. Treating the experimental rats with the methanolic extract of a classical ayurvedic formulation-Bru-Satabari at portion 400 mg/kg modifies rats inactivity to excruciating warm upgrade in tail flick tests. These discoveries recommend that central and peripheral systems are engaged with the antinociceptive movement of the extract. The Methanolic extract of a classical ayurvedic formulation-Bru Satabari acts at the most extreme portion (400 mg/kg) could ease the torment in all time of tail flick test. The results and experimental data were shown in Table 8.

At all time points except 60 minutes, the methanol extract Bru-Satabari exhibited significant analgesic activity by increasing the reaction time of the rats compared to the control (saline treated rats). Diazepam produced the most significant antinociception effect in comparison to the control during all observation times, followed by the extract. The tail-flick method is based on the discovery that morphine-like compounds selectively prolong the reaction time of rats' typical tail-withdrawal effect.

DISCUSSION

This HPTLC methodology may be beneficial for both identifying and assessing the quality of methanolic extract-containing preparations of Bru-Satabari-An ayurvedic classical medicine. From the study the extract showed two constituents which was

Table 3: Compounds identified by GC-MS analysis of Sukumaram Kashayam.

Sl. No	Compound name	Peak area%	Retention time in minutes	Molecular formula	Cas no.	Molecular weight	Pharmacological activity
1	Cannabidiol	31971587.00	13.89	C ₂₁ H ₃₀ O ₂	13956-29-1	314.464 g/mol	Can relieve pain, reduce anxiety and depression, can alleviate cancer related symptoms, reduce acne, have neuroprotective properties, could benefit heart health.
2	DELTA.8-Tetrahydrocannabinol	6078970.36	14.41	C ₂₁ H ₃₀ O ₂	5957-75-5	314.5 g/mol	Antiemetic, anxiolytic, appetite-stimulating, analgesic, and neuroprotective properties.
3	Cannabinol	4005108.33	14.79	C ₂₁ H ₂₆ O ₂	521-35-7	310.437 g/mol	CBN has strong sedative and relaxing properties, provide effective pain relief, CBN may stimulate the growth of bone marrow cells, used to stimulate appetite, is an anticonvulsant, and is anti-bacterial.

Table 4: Effect of methanolic extract of *Bru-Satabari* on Hole Cross Test in Mice.

Groups (n=6)	Treatment	Dose	0 min	30 min	60 min	90 min	120 min
I	Control	1% CMC	17.00 ± 0.83	18.80 ± 0.66	20.80 ± 0.97	19.00 ± 1.30	17.40 ± 0.51
II	Diazepam	1mg/kg	9.9±0.64	8.20±0.80**	7.8± 0.67***	6.20± 0.57***	3.66± 0.41***
III	Methanol extract	400mg/kg	10.80 ± 1.22	10.80 ±0.49**	9.80 ± 2.33***	7.00 ± 1.81***	4.00 ± 0.31***

The result presented as Mean ± S.E.M., the statistical analysis performed using one-way analysis of variance (ANOVA) followed by Dunnett's t test. Differences between groups were considered significant at a level of ***indicates $p < 0.001$, **indicates $p < 0.01$, indicates * $p < 0.05$

Table 5: Effect of methanolic extract of *Bru-Satabari* on Open Field Test in Mice.


Groups	Treatment	Dose	No. of square crossed				
			0 min	30 min	60 min	90 min	120 min
I	Control	1% CMC	102.80 ± 2.92	98.00 ± 2.81	97.40 ± 2.27	82.40 ± 2.69	72.00 ± 2.55
II	Diazepam	1mg/kg	94.00 ± 1.74	26.60 ± 1.81***	21.00 ± 1.20***	11.60 ± 0.51***	4.20 ± 0.56***
III	Methanol extract	400mg/kg	99.80 ± 2.43	87.00 ± 2.58**	84.20 ± 1.15***	21.40 ± 2.11***	15.60 ± 2.31**

The result presented as Mean ± S.E.M., the statistical analysis performed using one-way analysis of variance (ANOVA) followed by Dunnett's t test. Differences between groups were considered significant at a level of ***indicates $p < 0.001$, **indicates $p < 0.01$, indicates * $p < 0.05$

CIL/ SAIF Panjab University Chandigarh

Sample Header

Data File:	BS-1
Original Data Path:	C:\GCMS-DATA\YEAR 2019\JANUARY\16
Sample Type:	Unknown
Sample ID:	BS-1
Sample Name:	
Acquisition Date:	01/17/19 04:06:12 PM
Run Time(min):	18.75
Injection Volume(µl):	1.00
Scans:	5513
Low Mass(m/z):	50
High Mass(m/z):	700
Instrument Method:	C:\GCMS-data\instrument method\GERNAL-gcms-METHOD-D.meth



Qual Peak Table

RT	Peak Area	Area %	Peak Height
13.89	31971587.00	76.02	16805018.16
14.41	6078970.36	14.45	3048917.74
14.79	4005108.33	9.52	1639531.34

Figure 4: GC-MS chromatogram of Methanolic extract of Bru-Satabari, a classical ayurvedic formulation.

Table 6: Effect of methanolic extract of *Bru-Satabari* on Rota Rod Test in Mice.

Groups	Treatment	Dose	Performance time (s)	Number of falls
I	Control	1% CMC	175.00 ± 1.89	1.30 ± 0.64
II	Diazepam	1mg/kg	151.00 ± 1.54***	13.60 ± 0.40***
III	Methanol extract	400mg/kg	136.00 ± 1.22***	14.20 ± 0.73***

The result presented as Mean ± S.E.M., the statistical analysis performed using one-way analysis of variance (ANOVA) followed by Dunnett's t test. Differences between groups were considered significant at a level of ***indicates $p < 0.001$, **indicates $p < 0.01$, indicates * $p < 0.05$

Table 7: Effect of methanolic extract of *Bru-Satabari* on thiopental sodium-induced sleeping time test in mice.

Groups	Treatment	Dose		
I	Control	1% CMC	13.57 + 0.45	87.80 + 1.85
II	Diazepam	1mg/kg	6.72 + 0.06***	187.40 + 1.12***
III	Methanol extract	400mg/kg	8.50 + 0.22***	163.00 + 1.37***

The result presented as Mean ± S.E.M., the statistical analysis performed using one-way analysis of variance (ANOVA) followed by Dunnett's t test. Differences between groups were considered significant at a level of ***indicates $p < 0.001$, **indicates $p < 0.01$, indicates * $p < 0.05$

Table 8: Effect of methanolic extract of Bru-Satabari on Tail-immersion Test in Mice.

Groups	Treatment	Dose	0 min	30 min	60 min
I	Control	1% CMC	3.9±0.1	3.7±0.2	4.1±0.2
II	Diazepam	1mg/kg	3.9±0.1	9.4±0.1**	13.1±0.1**
III	Methanol extract	400mg/kg	4.1±0.2	8.0±0.2**	12.1±0.2**

The result presented as Mean ± S.E.M., the statistical analysis performed using one-way analysis of variance (ANOVA) followed by Dunnett's t test. Differences between groups were considered significant at a level of ***indicates $p < 0.001$, **indicates $p < 0.01$, indicates * $p < 0.05$

found that to have R_f value of 0.38 and 0.48 at 254 nm which indicates the presence of Tetrahydrocannabinol and cannabidiol respectively present in cannabis as per the previous literature.²²

The FTIR result conclude that methanol extract of Bru-Satavari include Cannabidiol as well as tetrahydrocannabinol component, having psychoactive properties. From the literature it was found that Cannabidiol does not appear to have any intoxicating effects such as those caused by THC.²³

The presence of compounds such as Cannabidiol, DELTA-8-Tetrahydrocannabinol, and Cannabinol in the formulation confirms the presence of cannabis. Furthermore, the presence of cannabis demonstrates neuropharmacological action.

GABA is the most important inhibitory neurotransmitter in the central nervous system. Distinctive anxiolytic, sedative hypnotic drug elucidate their activity through GABA_A receptor. Its sedative effect observed here could be due to a interaction with a chemical agent that adheres to a CNS receptor.

Therefore it is possible that methanolic extract of a classical ayurvedic formulation- Bru-Satabari may act by potentiating GABA restraint in the CNS or might be because of the initiation of the GABAergic receptor by the extract. GC-MS examination on the extract showed the presence of THC etc. which prompted the conclusion that phytoconstituents like THC present in the extract is responsible for sedative activity.²⁴ The decline number of holes crosses by diazepam treated mice contrasted with control might be because of the portion 1mg kg⁻¹ utilized in the standard that can deliver sedation in experimental animals.²⁵

The potential of Bru-satavari to suppress locomotor activity implies that it has central nervous system depressant activity, which was confirmed by GCMS analysis of the extract.²⁶

The fact that Bru-Satabari and diazepam have similar effects led experiment to believe that Bru-Satabari can have sedative effects in experimental mice, reducing both overall activity and motor coordination.²⁷ Our previous evidence supports the experimental data found in the thiopental sodium-induced sleeping period observation test. The sedative characteristics of a substance are investigated using this test, which is a standard procedure in behavioural pharmacology.

As anticipated, diazepam administration produced similar effects. Substantial evidence suggests that CNS depressants, such as medicinal phytoconstituents, bind to the gamma aminobutyric

acid type A (GABAA) receptor complex and end up causing postsynaptic neuron hyperpolarization.²⁸ Based on the findings of this study, cannabidiol (CBD) found in the formulation and endorsed by GC-MS data may have greater therapeutic potential for the treatment of insomnia.

Centrally acting analgesics raise the pain threshold of animals in response to pressure and heat.²⁹ As a result, the extract's onset of action on this pain-state model suggests that it may be acting centrally due to the presence of cannabinol. At all time points, the extract's tail-flick latency was less than that of the reference drug. According to the investigation, BruSatabari may be a better natural alternative for mild pain relief.

CONCLUSION

The analytical data presented here makes it possible the key phytoconstituents spotted in the Ayurvedic formulation to be ascertained. Cannabinoids' identification, isolated from or reveal in ayurvedic therapies would be facilitated by expressing all analytical measurements taken under standardised conditions. The presence and number of substances in the herbal formulation were ascertained using HPTLC. The presence of cannabidiol substances in the Ayurvedic formulation was affirmed by the FTIR result obtained. The FTIR result conclude that methanol extract of BruSatavari include Cannabidiol as well as tetrahydrocannabinol component. Finally, the use of GCMS made It is possible to identify all of the tests performed phytoconstituents especially cannabinoids in one single analysis, even in the low ng/mL concentration range. The sedative effect of the formulation is due to the presence of cannabinoids, methanolic extract BruSatabari may act by potentiating GABA restraint in the CNS or might be because of the initiation of the GABAergic receptor by the extract. Bru-satavari's ability to suppress locomotor activity suggests that it has a central nervous system depressant activity due to the presence of cannabinoids as confirmed in GCMS analysis of the extract. The fact that Bru-Satabari effects led us to believe that the ayurvedic drugs can have sedative effects in experimental mice, reducing both overall activity and motor coordination. The outcome or results found in the thiopental sodium-induced sleeping period observation test have been further supported by our above-mentioned evidence. The formulation's onset of action on this pain-state model suggests that it may be going to act centrally due to the presence of cannabinol. According to the study, Bru-Satabari may be a better

natural solution for fairly benign pain relief. However, additional research can be conducted to determine the phytoconstituents responsible for the mechanism of action involved.

ACKNOWLEDGEMENT

The authors are grateful to the management members and Principal, Institute of Pharmacy & Technology, Salipur for providing all facilities and encouragement throughout the work. The authors would like to thank the CIL/SAIF Panjab university, Chandigarh for carrying out the GC-MS analysis of Bru-Satabari.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ABBREVIATIONS

HPTLC: High performance thin layer chromatography; **TLC:** Thin layer chromatography, **v/v-volume** by volume; **ATR FTIR:** Attenuated Total reflection Fourier transform infrared, **GC-MS:** Gas chromatography and mass spectrometry **ev-electro volt;** **NIST:** databases-National Institute of Standard and Technology database; **cm:** Centimeter **n:** Number; **mg/kg:** Milligram/Kilogram; **°C:** Degree centigrade; **R_f** Retention factor; **CB1:** Cannabinoid receptor type 1; **THC:** Tetrahydrocannabinol; **GABA:** Gamma-aminobutyric acid; **CIL/SAIF:** Central Instrument laboratory/Sofisticated analytical instrument facility.

REFERENCES

- Yeung AWK, Tzvetkov NT, Atanasov AG. When neuroscience meets pharmacology: A neuropharmacology literature analysis. *Front Neurosci.* 2018;12:852. doi:10.3389/fnins.2018.00852, PMID 30505266.
- Everitt BJ, Robbins TW. Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. *Nat Neurosci.* 2005;8(11):1481-9. doi: 10.1038/nn1579, PMID 16251991.
- Andre CM, Hausman JF, Guerriero G. *Cannabis sativa*: the Plant of the Thousand and One Molecules. *Front Plant Sci.* 2016;7:19. doi:10.3389/fpls.2016.00019, PMID 26870049.
- ElSohly MA, Gul W. Constituents of *Cannabis sativa*. In: Pertwee RG, editor. *Handbook of cannabis*. Oxford: Oxford University Press; 2014. p.3-10.
- Fride E, Perchuk A, Hall FS, Uhl GR, Onaivi ES. Behavioral methods in cannabinoid research. *Methods Mol Med.* 2006; 123:269-90. doi:10.1385/1-59259-999-0:269, PMID 16506414.
- Grant BF, Pickering R. The relationship between cannabis use and DSM-IV cannabis abuse and dependence: results from the National Longitudinal Alcohol Epidemiologic Survey. *J Subst Abuse.* 1998;10(3):255-64. doi: 10.1016/s0899-3289(99)00006-1, PMID 10689658.
- Daharwal SJ, Shrivastava S. Preliminary Phytochemical Screening and HPTLC Fingerprinting of Extracts of *Thuja occidentalis*. *Res J Pharm Technol.* 2019; 12(10):4782-4. 10.5958/0974-360X.2019.00825.4
- Alam P, Alajmi MF, Siddiqui NA, Al-Rehaily AJ, Basudan OA. Determination of bioactive marker glycyrrhizin in Glycyrrhizaglabarroot and commercial formulation by validated HPTLC-densitometric method. *J Coast Life Med.* 2014;2(11):882-87. doi:10.12980/JCLM.2.20143D372.
- Valh JV, Peršin Z, Voňčina B, Vrezner K, Tušek L, L.FrasZemljič. Microencapsulation of cannabidiol in liposomes as Coating for cellulose for potential advanced sanitary material. *Coatings.* 2021;11(1):1-18.
- Subhan N, Alam MA, Ahmed F, Shahid IJ, Nahar L, Sarker SD. Bio activity of *Excoecaria agallocha*. *Rev bras farmacogn.* 2008;18(4):521-6. doi: 10.1590/S0102-695X2008000400004.
- Shahed-Al-Mahmud Md, Lina SMM. Evaluation of sedative and anxiolytic activities of methanol extract of leaves of *Persicaria hydropiper* in mice. *Clin Phytosci.* 2017; 3(1):20. doi:10.1186/s40816-017-0056-5.
- Chatterjee M, Verma P, Maurya R, Palit G. Evaluation of ethanol leaf extract of *Ocimum sanctum* in experimental models of anxiety and depression. *Pharm Biol.* 2011;49(5):477-83. doi: 10.3109/13880209.2010.523832, PMID 21281248.
- Moniruzzaman M, Rahman MA, Ferdous A. Evaluation of sedative and hypnotic activity of ethanolic extract of *Scopariadulcis* Linn. *Evid Based Complement Alternat Med.* 2015;873954. doi:10.1155/2015/873954, PMID 25861372.
- Sumanta M, Debjit G, Seru G, Onkar M, Venkata RM, Vankayalpati R. Evaluation of analgesic, antipyretic and anti-inflammatory effects of ethanol extract from fern species *Macrothelypteris torresiana* (Gaudich.) Aerial parts. *Pharmacognosy Commun.* 2016;6(2):57-63. doi: 10.5530/pc.2016.2.2.
- Available from: <https://www.swgdrug.org/Monographs/MARIJUANA.pdf>.
- Fernández-Ruiz J, Sagredo O, Pazos MR, García C, Pertwee R, Mechoulam R, et al. Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid? *Br J Clin Pharmacol.* 2013;75(2):323-33. doi:10.1111/j.1365-2125.2012.04341.x. PMID 22625422.
- [cited in 30/5/2021] Available from: <https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C61312>.
- Kleckner AS, Kleckner IR, Kamen CS, Tejani MA, Janelsins MC, Morrow GR, et al. Opportunities for cannabis in supportive care in cancer. *Ther Adv Med Oncol.* 2019; 11:1-29. doi: 10.1177/1758835919866362. eCollection. PMID 31413731.
- Pickens JT. Sedative activity of cannabis in relation to its delta-9-tetrahydrocannabinol and cannabidiol content. *Br J Pharmacol.* 1981;72(4):649-56. doi: 10.1111/j.1476-5381.1981.tb09145.x, PMID 6269680.
- Karler R, Cely W, Turkkanis SA. The anticonvulsant activity of cannabidiol and cannabiniol. *Life Sci.* 1973;13(11):1527-31. doi: 10.1016/0024-3205(73)90141-0, PMID 4768980.
- Van Klinger B, Ten Ham M. Antibacterial activity of delta-9-tetrahydrocannabinol and cannabidiol. *Antonie Leeuwenhoek.* 1976;42(1-2):9-12. doi: 10.1007/BF00399444, PMID 1085130.
- UNODC. Recommended methods for the identification and analysis of cannabis and cannabis products. New York: United Nations Publications; 2009.
- Available from: https://www.harricksci.com/sites/default/files/pdf/application_notes/DiaMaxATR_App-Notes_Medical_Cannabinoids.pdf.
- Atakan Z. Cannabis, a complex plant: different compounds and different effects on individuals. *Ther Adv Psychopharmacol.* 2012;2(6):241-54. doi: 10.1177/2045125312457586, PMID 23983983.
- Takeda H, Tsuji M, Matsumiya T. Changes in head-dipping behavior in the hole-board test reflect the anxiogenic and/or anxiolytic state in mice. *Eur J Pharmacol.* 1998;350(1):21-9. doi:10.1016/s0014-2999(98)00223-4, PMID 9683010.
- Iversen L. Cannabis and the brain. *Brain.* 2003;126(6):1252-70. doi: 10.1093/brain/awg143, PMID 12764049.
- Tirumalasetti J, Patel M, Shaikh U, Harini K, Shankar J. Evaluation of skeletal muscle relaxant activity of aqueous extract of *Nerium oleander* flowers in Albino rats. *Indian J Pharmacol.* 2015;47(4):409-13. doi: 10.4103/0253-7613.161265, PMID 26288474.
- Anisuzzaman Md, Hasan M, Acharzo AK, Das AK, Rahman S. *In vivo* and *in vitro* evaluation of pharmacological potentials of secondary bioactive metabolites of *Dalbergia candanensis* leaves. *Evid Based Complement Alternat Med.* 2017;2017:5034827. doi: 10.1155/2017/5034827, PMID 29441113.
- Fan SH, Ali NA, Basri DF. Evaluation of analgesic activity of the methanol extract from the galls of *Quercus infectoria* (Olivier) in rats. *Evid Based Complement Alternat Med.* 2014;2014:976764. doi: 10.1155/2014/976764, PMID 25254062.

Cite this article: Dash S, Sahoo AC, Sahoo PK, Rout SK, Jena P, Barik R, et al. Evaluation of Classical Ayurvedic Medicine for its Neuropharmacological Action. *Running Title. Int. J. Pharm. Investigation.* 2023;13(3):503-11.